Company: DAWN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001193125-25-264649
Chunk: 134

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Item 2
Chunk 134
---
% for the 12 patients with a BRAF V600 mutation. 

•The ORR was 51% among the 45 patients who had received a prior MAPK-targeted therapy, and 55% among the 31 patients who had not received a prior MAPK-targeted therapy.

•As of the May 10, 2024 data cutoff, the median duration of response by RAPNO LGG was 18.0 months (95% CI: 12.0, 22.8). In Arm 1, of the 77 patients enrolled, 66 (85.7%) patients have discontinued primary tovorafenib